Precision Biologics
Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products. The company focuses on developing targeted antibodies, antibody-drug conjugates, and companion diagnostics to enhance cancer treatment and early detection. Their mission is to develop precision-targeted diagnostics and therapeutics to extend and improve the quality of life for cancer patients.
Industries
Nr. of Employees
small (1-50)
Precision Biologics
4922 Fairmont Avenue, Suite 320, Bethesda, MD 20814
Patents
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-12344676-B2
View DetailsRecombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-11952429-B2
View DetailsRecombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-11572413-B2
View DetailsHumanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US-11505604-B2
View Details
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-12344676-B2
View DetailsRecombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-11952429-B2
View DetailsRecombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US-11572413-B2
View DetailsHumanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
US-11505604-B2
View DetailsProducts
Clinical-stage monoclonal antibody therapeutics targeting tumor neo-epitopes
Therapeutic monoclonal antibodies that bind tumor-specific neo-epitopes and engage immune effector mechanisms; candidates advanced into clinical studies for solid tumors.
Antibody–drug conjugate candidates
Antibody–drug conjugate candidates created by attaching cytotoxic payloads to optimized antibodies and evaluated in preclinical and early clinical studies.
Companion diagnostic assays for patient selection and monitoring
Validated tissue IHC assays and blood-based ELISA tests used to detect tumor antigen expression and to pre-select patients likely to respond to antibody therapies or to monitor treatment.
Clinical-stage monoclonal antibody therapeutics targeting tumor neo-epitopes
Therapeutic monoclonal antibodies that bind tumor-specific neo-epitopes and engage immune effector mechanisms; candidates advanced into clinical studies for solid tumors.
Antibody–drug conjugate candidates
Antibody–drug conjugate candidates created by attaching cytotoxic payloads to optimized antibodies and evaluated in preclinical and early clinical studies.
Companion diagnostic assays for patient selection and monitoring
Validated tissue IHC assays and blood-based ELISA tests used to detect tumor antigen expression and to pre-select patients likely to respond to antibody therapies or to monitor treatment.
Services
Sponsor and operational coordination services for oncology clinical trials including multicenter Phase I–IIb studies and combination therapy protocols; includes public protocol registration.
Laboratory-based development, qualification and validation of tissue IHC and blood-based ELISA assays for patient selection and treatment monitoring, with preparation of validation documentation for regulatory review.
In-house engineering, affinity maturation, biochemical and functional characterization of antibody candidates to optimize target binding and therapeutic activity.
Design and execution of cell-based assays and in vivo tumor model studies to evaluate efficacy, mechanism of action and immune engagement of therapeutic candidates.
Preparation and delivery of scientific presentations, abstracts and posters for major conferences, and support for drafting peer-reviewed manuscripts and disclosure materials.
Sponsor and operational coordination services for oncology clinical trials including multicenter Phase I–IIb studies and combination therapy protocols; includes public protocol registration.
Laboratory-based development, qualification and validation of tissue IHC and blood-based ELISA assays for patient selection and treatment monitoring, with preparation of validation documentation for regulatory review.
In-house engineering, affinity maturation, biochemical and functional characterization of antibody candidates to optimize target binding and therapeutic activity.
Design and execution of cell-based assays and in vivo tumor model studies to evaluate efficacy, mechanism of action and immune engagement of therapeutic candidates.
Preparation and delivery of scientific presentations, abstracts and posters for major conferences, and support for drafting peer-reviewed manuscripts and disclosure materials.
Expertise Areas
- Monoclonal antibody therapeutics
- Antibody–drug conjugate development
- Companion diagnostic development (IHC, ELISA)
- Clinical trial management for oncology (Phase I–IIb, multicenter)
Key Technologies
- Monoclonal antibody engineering
- Antibody–drug conjugation
- Immunohistochemistry (IHC)
- Enzyme-linked immunosorbent assay (ELISA)
News & Updates
Participation in the 7th International Neoantigen Summit in Amsterdam, Netherlands, from April 29 to May 1, 2024.
Presentation at Immuno 2024 in London, UK, on April 25-26, 2024.
Dr. Philip M Arlen, CEO of Precision Biologics, will deliver the opening keynote at the Festival of Biologics in San Diego, CA, on April 15, 2024.
Participation in the AACR 2024 Annual Meeting in San Diego, CA, where recent scientific data will be presented.
Dr. Philip M. Arlen, President & CEO, will deliver scientific talks in Tokyo, Japan, on December 14-15, 2023.
An article titled “Cancer Vaccines-Improving Their Aim” in the April 2025 issue of GEN highlights the company's work.
Participation in the 7th International Neoantigen Summit in Amsterdam, Netherlands, from April 29 to May 1, 2024.
Presentation at Immuno 2024 in London, UK, on April 25-26, 2024.
Dr. Philip M Arlen, CEO of Precision Biologics, will deliver the opening keynote at the Festival of Biologics in San Diego, CA, on April 15, 2024.
Participation in the AACR 2024 Annual Meeting in San Diego, CA, where recent scientific data will be presented.
Dr. Philip M. Arlen, President & CEO, will deliver scientific talks in Tokyo, Japan, on December 14-15, 2023.
An article titled “Cancer Vaccines-Improving Their Aim” in the April 2025 issue of GEN highlights the company's work.